AbbVie (NYSE:ABBV) said it now expects to report acquired IPR&D and milestone expenses of $1.6B on a pre-tax basis for Q4, which will lower GAAP and non-GAAP earnings by $0.88 per share. The drugmaker ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback